Rentabilitas dodolan miturut bathi resik Tourmaline Bio (TRML)

Net margin dynamics, with a metric at 0.00, demonstrate the monetization efficiency of Tourmaline Bio, Inc. (TRML) targeted drugs for individuals with autoimmune pathologies. Profit growth is based on the creation of interleukin-1 antibodies for the therapy of rare inflammations. Research stability is ensured by the diversification of production sites and strict control over the supply of biopharmaceutical raw materials.
TRML (Tourmaline): rincian analitis lan laporan miturut indikator

For Tourmaline Bio, Inc. (TRML), as an R&D startup, the net margin reflects capital management efficiency in the absence of commercial sales and the dependence on financing costs. This metric calculates the share of net income in revenue after deducting all operating and financial expenses, allowing investors to assess the fundamental stability of assets and their exposure to drug development costs.